{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:54:14Z","timestamp":1793760854575,"version":"4.6.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Chronic migraine (CM) is associated with substantial economic burden. Real-world data suggests that onabotulinumtoxinA treatment for CM reduces healthcare resource utilisation (HRU) and related costs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>REPOSE was a 2-year prospective, multicentre, non-interventional, observational study to describe the real-world use of onabotulinumtoxinA in adult patients with CM. This analysis examined the impact of onabotulinumtoxinA on HRU. Patients received onabotulinumtoxinA treatment approximately every 12\u2009weeks according to their physicians\u2019 discretion, guided by the summary of product characteristics (SPC) and PREEMPT injection paradigm. HRU outcome measures were collected at baseline and all administration visits and included headache-related hospitalizations and healthcare professional (HCP) visits. Health economic data, including family doctor and specialist visits, inpatient treatment for headache, acupuncture, technical diagnostics, use of nonpharmacologic remedies, and work productivity were also collected for patients enrolled at German study centres.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 641 patients were enrolled at 78 study centres across 7 countries (Germany, UK, Italy, Spain, Norway, Sweden, and Russia), 633 received \u22651 onabotulinumtoxinA dose, and 128 completed the 2-year study. Patients were, on average, aged 45\u2009years, 85% were female, and 60% (<jats:italic>n<\/jats:italic>\u2009=\u2009377) were from Germany. At the end of the 2-year observation period, significantly fewer patients reported headache-related hospitalizations (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.02) and HCP visits (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) within the past 3\u2009months than in the 3\u2009months before baseline. In the German population, reductions were observed across all health services at all follow-up visits compared with baseline. The percentage of patients who saw a family doctor decreased from 41.7% at baseline to 13.5% at administration visit 8 and visits to a medical specialist decreased from 61.7% to 5.2% of patients. Inpatient acute treatment and technical diagnostics declined from 6.4% and 19.7% of patients at baseline to 0.0% and 1.0% at administration 8, respectively. The use of nonpharmacologic remedies and medication for the acute treatment of migraine also decreased with continued onabotulinumtoxinA treatment. Work incapacity, disability, absenteeism, and impaired performance at school\/work improved with onabotulinumtoxinA treatment for CM over the 2-year observation period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Real-world evidence from REPOSE demonstrates that onabotulinumtoxinA treatment is associated with decreased HRU and supports the long-term benefits associated with the use of onabotulinumtoxinA for CM in clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01686581\">NCT01686581<\/jats:ext-link>. Name of registry: ClinicalTrials.gov. URL of registry: Date of retrospective registration: September 18, 2012. Date of enrolment of first patient: July 23, 2012.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-021-01260-4","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T12:11:34Z","timestamp":1622635894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study"],"prefix":"10.1186","volume":"22","author":[{"given":"Katja","family":"Kollewe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charly","family":"Gaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Gendolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"issue":"1","key":"1260_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1\u2013211","journal-title":"Cephalalgia"},{"issue":"5","key":"1260_CR2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","volume":"30","author":"JL Natoli","year":"2010","unstructured":"Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB (2010) Global prevalence of chronic migraine: a systematic review. Cephalalgia 30(5):599\u2013609. https:\/\/doi.org\/10.1111\/j.1468-2982.2009.01941.x","journal-title":"Cephalalgia"},{"issue":"3","key":"1260_CR3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.pain.2012.12.010","volume":"154","author":"MS Yoon","year":"2013","unstructured":"Yoon MS, Manack A, Schramm S, Fritsche G, Obermann M, Diener HC, Moebus S, Katsarava Z (2013) Chronic migraine and chronic tension-type headache are associated with concomitant low back pain: results of the German headache consortium study. Pain 154(3):484\u2013492. https:\/\/doi.org\/10.1016\/j.pain.2012.12.010","journal-title":"Pain"},{"issue":"8","key":"1260_CR4","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/head.13613","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Fanning KM, Reed ML, Murray S, Dumas PK, Adams AM, Lipton RB (2019) Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 59(8):1286\u20131299. https:\/\/doi.org\/10.1111\/head.13613","journal-title":"Headache"},{"issue":"5","key":"1260_CR5","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.mayocp.2016.02.013","volume":"91","author":"DC Buse","year":"2016","unstructured":"Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Manack Adams A, Lipton RB (2016) Impact of migraine on the family: perspectives of people with migraine and their spouse\/domestic partner in the CaMEO study. Mayo Clin Proc 91(5):596\u2013611. https:\/\/doi.org\/10.1016\/j.mayocp.2016.02.013","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"1260_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/0333102414552532","volume":"35","author":"AM Adams","year":"2015","unstructured":"Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM, Lipton RB (2015) The impact of chronic migraine: the chronic migraine epidemiology and outcomes (CaMEO) study methods and baseline results. Cephalalgia 35(7):563\u2013578. https:\/\/doi.org\/10.1177\/0333102414552532","journal-title":"Cephalalgia"},{"issue":"3","key":"1260_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","volume":"31","author":"AM Blumenfeld","year":"2011","unstructured":"Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, Goadsby PJ, Lipton RB (2011) Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the international burden of migraine study (IBMS). Cephalalgia 31(3):301\u2013315. https:\/\/doi.org\/10.1177\/0333102410381145","journal-title":"Cephalalgia"},{"issue":"1","key":"1260_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11916-013-0385-0","volume":"18","author":"M Lanteri-Minet","year":"2014","unstructured":"Lanteri-Minet M (2014) Economic burden and costs of chronic migraine. Curr Pain Headache Rep 18(1):385. https:\/\/doi.org\/10.1007\/s11916-013-0385-0","journal-title":"Curr Pain Headache Rep"},{"issue":"5","key":"1260_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10194-012-0460-7","volume":"13","author":"LM Bloudek","year":"2012","unstructured":"Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, Varon SF, Blumenfeld AM, Katsarava Z, Pascual J, Lanteri-Minet M, Cortelli P, Martelletti P (2012) Cost of healthcare for patients with migraine in five European countries: results from the international burden of migraine study (IBMS). J Headache Pain 13(5):361\u2013378. https:\/\/doi.org\/10.1007\/s10194-012-0460-7","journal-title":"J Headache Pain"},{"issue":"10","key":"1260_CR10","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1111\/head.12456","volume":"54","author":"JF Rothrock","year":"2014","unstructured":"Rothrock JF, Bloudek LM, Houle TT, Andress-Rothrock D, Varon SF (2014) Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine. Headache 54(10):1565\u20131573. https:\/\/doi.org\/10.1111\/head.12456","journal-title":"Headache"},{"key":"1260_CR11","unstructured":"BOTOX\u00ae [Package Insert]. Westport, County Mayo, Ireland: Allergan Pharmaceuticals; 2014."},{"issue":"7","key":"1260_CR12","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT 1 Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30(7):793\u2013803. https:\/\/doi.org\/10.1177\/0333102410364676","journal-title":"Cephalalgia"},{"issue":"7","key":"1260_CR13","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, PREEMPT 2 Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7):804\u2013814. https:\/\/doi.org\/10.1177\/0333102410364677","journal-title":"Cephalalgia"},{"issue":"9","key":"1260_CR14","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","volume":"51","author":"SK Aurora","year":"2011","unstructured":"Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE et al (2011) OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 51(9):1358\u20131373. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.01990.x","journal-title":"Headache"},{"issue":"9","key":"1260_CR15","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","volume":"50","author":"A Blumenfeld","year":"2010","unstructured":"Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ (2010) Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 50(9):1406\u20131418. https:\/\/doi.org\/10.1111\/j.1526-4610.2010.01766.x","journal-title":"Headache"},{"issue":"1","key":"1260_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s10194-018-0840-8","volume":"19","author":"AM Blumenfeld","year":"2018","unstructured":"Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack AA (2018) Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 19(1):13. https:\/\/doi.org\/10.1186\/s10194-018-0840-8","journal-title":"J Headache Pain"},{"issue":"1","key":"1260_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10194-019-0976-1","volume":"20","author":"F Ahmed","year":"2019","unstructured":"Ahmed F, Gaul C, Garcia-Monco JC, Sommer K, Martelletti P, Investigators RP (2019) An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain 20(1):26. https:\/\/doi.org\/10.1186\/s10194-019-0976-1","journal-title":"J Headache Pain"},{"issue":"5","key":"1260_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00702-016-1539-0","volume":"123","author":"K Kollewe","year":"2016","unstructured":"Kollewe K, Escher CM, Wulff DU, Fathi D, Paracka L, Mohammadi B, Karst M, Dressler D (2016) Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting. J Neural Transm (Vienna) 123(5):533\u2013540. https:\/\/doi.org\/10.1007\/s00702-016-1539-0","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"1260_CR19","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s40122-021-00253-0","volume":"10","author":"R Ornello","year":"2021","unstructured":"Ornello R, Ahmed F, Negro A, Miscio AM, Santoro A, Alpuente A, Russo A, Silvestro M, Cevoli S, Brunelli N, Vernieri F, Grazzi L, Baraldi C, Guerzoni S, Andreou AP, Lambru G, Frattale I, Kamm K, Ruscheweyh R, Russo M, Torelli P, Filatova E, Latysheva N, Gryglas-Dworak A, Straburzynski M, Butera C, Colombo B, Filippi M, Pozo-Rosich P, Martelletti P, Sacco S (2021) Early management of OnabotulinumtoxinA treatment in chronic migraine: insights from a real-life European multicenter study. Pain Ther 10(1):637\u2013650. https:\/\/doi.org\/10.1007\/s40122-021-00253-0","journal-title":"Pain Ther"},{"issue":"1","key":"1260_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/13696998.2019.1675417","volume":"23","author":"G Hollier-Hann","year":"2020","unstructured":"Hollier-Hann G, Curry A, Onishchenko K, Akehurst R, Ahmed F, Davies B, Keyzor I (2020) Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK. J Med Econ 23(1):113\u2013123. https:\/\/doi.org\/10.1080\/13696998.2019.1675417","journal-title":"J Med Econ"},{"issue":"1","key":"1260_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s10194-017-0802-6","volume":"18","author":"B Davies","year":"2017","unstructured":"Davies B, Gaul C, Martelletti P, Garcia-Monco JC, Brown S (2017) Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data. J Headache Pain 18(1):93. https:\/\/doi.org\/10.1186\/s10194-017-0802-6","journal-title":"J Headache Pain"},{"issue":"3","key":"1260_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1046\/j.1526-4610.2000.00030.x","volume":"40","author":"BC Martin","year":"2000","unstructured":"Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, Jhingran P (2000) Validity and reliability of the migraine-specific quality of life questionnaire (MSQ version 2.1). Headache 40(3):204\u2013215. https:\/\/doi.org\/10.1046\/j.1526-4610.2000.00030.x","journal-title":"Headache"},{"issue":"3","key":"1260_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4081\/monaldi.2012.121","volume":"78","author":"G Balestroni","year":"2012","unstructured":"Balestroni G, Bertolotti G (2012) EuroQol-5D (EQ-5D): an instrument for measuring quality of life. Monaldi Arch Chest Dis 78(3):155\u2013159. https:\/\/doi.org\/10.4081\/monaldi.2012.121","journal-title":"Monaldi Arch Chest Dis"},{"issue":"10159","key":"1260_CR24","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"GBD Disease","year":"2018","unstructured":"Disease GBD, Injury I, Prevalence C (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of Disease study 2017. Lancet 392(10159):1789\u20131858","journal-title":"Lancet"},{"issue":"12","key":"1260_CR25","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1136\/jnnp-2013-305197","volume":"84","author":"JC Sanderson","year":"2013","unstructured":"Sanderson JC, Devine EB, Lipton RB, Bloudek LM, Varon SF, Blumenfeld AM, Goadsby PJ, Buse DC, Sullivan SD (2013) Headache-related health resource utilisation in chronic and episodic migraine across six countries. J Neurol Neurosurg Psychiatry 84(12):1309\u20131317. https:\/\/doi.org\/10.1136\/jnnp-2013-305197","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1260_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-019-1068-y","volume":"20","author":"A Negro","year":"2019","unstructured":"Negro A, Sciattella P, Rossi D, Guglielmetti M, Martelletti P, Mennini FS (2019) Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre. J Headache Pain 20(1):120. https:\/\/doi.org\/10.1186\/s10194-019-1068-y","journal-title":"J Headache Pain"},{"issue":"1","key":"1260_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/JOM.0b013e3181c1dc56","volume":"52","author":"WF Stewart","year":"2010","unstructured":"Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB (2010) Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med 52(1):8\u201314. https:\/\/doi.org\/10.1097\/JOM.0b013e3181c1dc56","journal-title":"J Occup Environ Med"},{"issue":"Suppl 1","key":"1260_CR28","first-page":"108","volume":"59","author":"JFSR Rothrock","year":"2019","unstructured":"Rothrock JFSR, Sommer K, Blumenfeld AM (2019) Healthcare resource utilization in adult patients treated with Onabotulinumtoxina for Chronic Migraine: results from the COMPEL study. Headache 59(Suppl 1):108","journal-title":"Headache"},{"issue":"Suppl 15","key":"1260_CR29","first-page":"P4.10","volume":"92","author":"GBW Boudreau","year":"2019","unstructured":"Boudreau GBW, Graboski C, Ong-Lam M, Finkelstein I, Christie S, Bhogal M, Davidovic G (2019) Impact of onabotulinumtoxinA on quality of life, health resource utilization, and work productivity in people with chronic migraine: interim results from a prospective, observational study (PREDICT). Neurology 92(Suppl 15):P4.10\u2013P4023","journal-title":"Neurology"},{"issue":"1","key":"1260_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.17116\/jnevro201911901131","volume":"119","author":"MV Naprienko","year":"2019","unstructured":"Naprienko MV, Smekalkina LV, Safonov MI, Filatova EG, Latysheva NV, Ekusheva EV, Artemenko AR, Osipova VV, Baiushkina LI (2019) Real-world migraine burden: clinical and economic aspects. Zh Nevrol Psikhiatr Im S S Korsakova 119(1):31\u201337. https:\/\/doi.org\/10.17116\/jnevro201911901131","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"issue":"9","key":"1260_CR31","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1177\/0333102415621294","volume":"36","author":"Z Hepp","year":"2016","unstructured":"Hepp Z, Rosen NL, Gillard PG, Varon SF, Mathew N, Dodick DW (2016) Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: retrospective analysis of a US-based insurance claims database. Cephalalgia 36(9):862\u2013874. https:\/\/doi.org\/10.1177\/0333102415621294","journal-title":"Cephalalgia"},{"issue":"7","key":"1260_CR32","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3111\/13696998.2013.802694","volume":"16","author":"AJ Batty","year":"2013","unstructured":"Batty AJ, Hansen RN, Bloudek LM, Varon SF, Hayward EJ, Pennington BW, Lipton RB, Sullivan SD (2013) The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK. J Med Econ 16(7):877\u2013887. https:\/\/doi.org\/10.3111\/13696998.2013.802694","journal-title":"J Med Econ"},{"issue":"1","key":"1260_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s10194-020-01162-x","volume":"21","author":"A Hansson-Hedblom","year":"2020","unstructured":"Hansson-Hedblom A, Axelsson I, Jacobson L, Tedroff J, Borgstrom F (2020) Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway. J Headache Pain 21(1):99. https:\/\/doi.org\/10.1186\/s10194-020-01162-x","journal-title":"J Headache Pain"},{"issue":"Suppl 1","key":"1260_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10072-014-1741-5","volume":"35","author":"M Ruggeri","year":"2014","unstructured":"Ruggeri M (2014) The cost effectiveness of Botox in Italian patients with chronic migraine. Neurol Sci 35(Suppl 1):45\u201347. https:\/\/doi.org\/10.1007\/s10072-014-1741-5","journal-title":"Neurol Sci"},{"issue":"1","key":"1260_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s10194-020-01180-9","volume":"21","author":"S Kikui","year":"2020","unstructured":"Kikui S, Chen Y, Todaka H, Asao K, Adachi K, Takeshima T (2020) Burden of migraine among Japanese patients: a cross-sectional National Health and wellness survey. J Headache Pain 21(1):110. https:\/\/doi.org\/10.1186\/s10194-020-01180-9","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01260-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-021-01260-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01260-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T12:11:42Z","timestamp":1622635902000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-021-01260-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,2]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1260"],"URL":"https:\/\/doi.org\/10.1186\/s10194-021-01260-4","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,2]]},"assertion":[{"value":"14 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Before study initiation, all investigators obtained ethical approval from their respective ethics committees. The study was conducted in accordance with the International Council on Harmonisation Guideline for Good Clinical Practice. Informed consent was obtained from each patient before enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Financial arrangements of the authors with companies whose products may be related to the present report are listed below, as declared by the authors.<b>Katja Kollewe, MD<\/b>, has received travel grants and honoraria for lectures or advisory boards from Allergan, an AbbVie Company, Biogen, Ipsen, Lilly, Merz, Novartis, and Teva. KK does not hold stocks of any pharmaceutical or medical device companies. <b>Charly Gaul, MD<\/b>, has received honoraria for consulting and lectures within the past three years from Allergan, an AbbVie Company, Lilly, Novartis Pharma, Hormosan Pharma, Gr\u00fcnenthal, Sanofi-Aventis, Weber & Weber, Lundbeck and TEVA. He does not hold any stocks of pharmaceutical companies. He is honorary secretary of the German Migraine and Headache Society. <b>Astrid Gendolla, MD<\/b>, has received fees for lectures and consulting in the last 3\u2009years from Allergan, an AbbVie Company, Reckitt Benckiser, St. Jude Medical, Bayer, Gr\u00fcnenthal, Mundipharma, Zahn\u00e4rztekammer KVNO, GAF, Novartis, Lilly, Perfood, and Teva. She does not hold stocks of any pharmaceutical companies. She is vice president of the German Pain Society. <b>Katherine Sommer, PhD<\/b>, is an employee of AbbVie Inc. and receives stock or stock options.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}